Analysis Tools
neoplasm
|
• mice normal for about 4 weeks after polyI/polyC injection
• begin to develop cancers after 4 weeks
• 100% develop tumors with a median onset of 11 weeks after polyI/polyC injection
• sometimes an increase in circulating tumor cells
|
|
• 3 out of 23 mice with rhabdoid tumors
|
|
• periportal lymphoma in the liver
|
|
• 20 of 23 mice have CD8+ T cell lymphomas
• tumor cell types suggestive of malignant lymphocytes
|
immune system
|
• 20 of 23 mice have CD8+ T cell lymphomas
• tumor cell types suggestive of malignant lymphocytes
|
|
• increase in circulating eosinophiles
|
|
• effacement of normal architecture
|
|
• sometimes dramatically
|
|
• effacement of the normal architecture of involved lymph nodes
|
hematopoietic system
|
• 20 of 23 mice have CD8+ T cell lymphomas
• tumor cell types suggestive of malignant lymphocytes
|
|
• often a mild and progressive decrease in blood cell counts
|
|
• increase in circulating eosinophiles
|
|
• effacement of normal architecture
|
|
• sometimes dramatically
|
liver/biliary system
|
• periportal lymphomas
|
|
• sometimes dramatically
|
cellular
|
• in liver and spleen 18-24 hours after polyI/polyC injection
|
endocrine/exocrine glands
|
• 20 of 23 mice have CD8+ T cell lymphomas
• tumor cell types suggestive of malignant lymphocytes
|
growth/size/body
|
• sometimes dramatically
|
|
• sometimes dramatically
|
muscle
|
• 3 out of 23 mice with rhabdoid tumors
|
